ArticleFrontiers in pharmacology2026
Cerevisterol from
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Liver fibrosis is a critical pathological process to irreversible cirrhosis. The valued Methods: The metabolites were extracted and purified by petroleum ether, ethanol reflux extraction and chromatographic separation technology. Their structures were identified based on extensive NMR and MS data. TGF-β1-induced LX-2 cells were employed to study the anti-inflammation activity of the isolated cerevisterol. The mRNA expression of Results: Cerevisterol, adenosine, uridine, ergosterol, 2-piperidone, L-tryptophan and (24S)-ergost-7(8)-en-3β,5α,6β-triol were obtained. In the TGF-β1-induced fibrosis model, cerevisterol (10 μM) and a commercial anti-liver fibrosis drug containing Chinese cordyceps (75 ng/mL) as positive control significantly suppressed cell proliferation at 72 and 96 hours. qRT-PCR analysis demonstrated that cerevisterol downregulated mRNA expression of Smad3, Smad4, and Collagen I. Western blot results confirmed reduced protein levels of Smad3 and Smad4 in the cerevisterol-treated cells. Discussion: Cerevisterol from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.